D.J. Back

2.9k total citations
80 papers, 2.2k citations indexed

About

D.J. Back is a scholar working on Pharmacology, Infectious Diseases and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, D.J. Back has authored 80 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pharmacology, 23 papers in Infectious Diseases and 20 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in D.J. Back's work include Pharmacogenetics and Drug Metabolism (26 papers), HIV/AIDS drug development and treatment (21 papers) and Drug Transport and Resistance Mechanisms (15 papers). D.J. Back is often cited by papers focused on Pharmacogenetics and Drug Metabolism (26 papers), HIV/AIDS drug development and treatment (21 papers) and Drug Transport and Resistance Mechanisms (15 papers). D.J. Back collaborates with scholars based in United Kingdom, Thailand and Germany. D.J. Back's co-authors include AM Breckenridge, GJ Moyle, J. Tjia, Michael Orme, P.H. Rowe, M.L'E. Orme, B.K. Park, M Bruce MacIver, Francesca E. Crawford and James L. Maggs and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, American Journal of Obstetrics and Gynecology and British Journal of Pharmacology.

In The Last Decade

D.J. Back

79 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D.J. Back United Kingdom 29 629 615 596 475 388 80 2.2k
DJ Back United Kingdom 24 313 0.5× 586 1.0× 347 0.6× 415 0.9× 354 0.9× 49 1.5k
Scott Penzak United States 31 196 0.3× 548 0.9× 1.0k 1.7× 325 0.7× 467 1.2× 99 3.1k
L.A. Salako Nigeria 30 1.4k 2.3× 466 0.8× 149 0.3× 325 0.7× 145 0.4× 118 2.6k
Richard C. Brundage United States 38 252 0.4× 315 0.5× 1.5k 2.4× 1.1k 2.3× 744 1.9× 136 3.8k
Vincent Jullien France 31 425 0.7× 238 0.4× 1.1k 1.9× 744 1.6× 351 0.9× 125 3.3k
Juan J.L. Lertora United States 24 156 0.2× 210 0.3× 399 0.7× 252 0.5× 185 0.5× 49 1.7k
John G. Gambertoglio United States 31 87 0.1× 210 0.3× 565 0.9× 379 0.8× 230 0.6× 91 2.4k
Indravadan H. Patel United States 27 144 0.2× 179 0.3× 381 0.6× 610 1.3× 224 0.6× 75 2.4k
James J. Keirns United States 34 121 0.2× 260 0.4× 1.5k 2.4× 256 0.5× 354 0.9× 88 3.9k
Keith Gallicano Canada 26 146 0.2× 533 0.9× 1.3k 2.2× 383 0.8× 320 0.8× 63 2.8k

Countries citing papers authored by D.J. Back

Since Specialization
Citations

This map shows the geographic impact of D.J. Back's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.J. Back with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.J. Back more than expected).

Fields of papers citing papers by D.J. Back

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.J. Back. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.J. Back. The network helps show where D.J. Back may publish in the future.

Co-authorship network of co-authors of D.J. Back

This figure shows the co-authorship network connecting the top 25 collaborators of D.J. Back. A scholar is included among the top collaborators of D.J. Back based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.J. Back. D.J. Back is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mora‐Peris, Borja, Adam Croucher, Laura Else, et al.. (2013). Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. Journal of Antimicrobial Chemotherapy. 68(6). 1348–1353. 11 indexed citations
2.
Lamorde, Mohammed, Pauline Byakika‐Kibwika, Máirín Ryan, et al.. (2010). Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy. 66(1). 180–183. 14 indexed citations
3.
Seden, Kay, D.J. Back, & SH Khoo. (2009). Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. Journal of Antimicrobial Chemotherapy. 64(1). 5–8. 27 indexed citations
4.
Dickinson, Laura, Marta Boffito, D.J. Back, et al.. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. Journal of Antimicrobial Chemotherapy. 63(6). 1233–1243. 28 indexed citations
5.
Almond, Lisa M., et al.. (2005). Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clinical Pharmacology & Therapeutics. 78(2). 132–142. 64 indexed citations
6.
Jones, Kevin F., et al.. (2001). Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS. 15(6). 675–681. 94 indexed citations
7.
Churchill, Duncan, Alexander S. Pym, S. Galpin, et al.. (1999). The Rabbit Study: Ritonavir and Saquinavir in Combination in Saquinavir-Experienced and Previously Untreated Patients. AIDS Research and Human Retroviruses. 15(13). 1181–1189. 5 indexed citations
8.
Kewn, Stephen, et al.. (1999). Intracellular Activation of 2',3'-Dideoxyinosine and Drug Interactions in Vitro. AIDS Research and Human Retroviruses. 15(9). 793–802. 20 indexed citations
9.
10.
Abel, Steffen, D.J. Back, James L. Maggs, & B.K. Park. (1993). Cortisol metabolism in vitro—II. Species difference. The Journal of Steroid Biochemistry and Molecular Biology. 45(5). 445–453. 23 indexed citations
11.
12.
Back, D.J., et al.. (1991). Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. The Journal of Steroid Biochemistry and Molecular Biology. 38(2). 219–225. 45 indexed citations
13.
Madden, Stephen F., et al.. (1990). Metabolism of the contraceptive steroid desogestrel by human liver in vitro. Journal of Steroid Biochemistry. 35(2). 281–288. 21 indexed citations
14.
Orme, Michael, D.J. Back, & S. Ball. (1989). Interindividual variation in the metabolism of ethynylestradiol. Pharmacology & Therapeutics. 43(2). 251–260. 32 indexed citations
15.
Stead, R J, S.F.M. Grimmer, Simon Rogers, et al.. (1987). Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.. Thorax. 42(1). 59–64. 25 indexed citations
16.
Karbwang, Juntra, D Bunnag, AM Breckenridge, & D.J. Back. (1987). The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. European Journal of Clinical Pharmacology. 32(2). 173–177. 38 indexed citations
17.
Grimmer, S.F.M., et al.. (1983). The effect of cotrimoxazole on oral contraceptive steroids in women. Contraception. 28(1). 53–59. 34 indexed citations
18.
Back, D.J., AM Breckenridge, Viveca Odlind, et al.. (1982). The enzyme inducing effect of rifampicin in the rhesus monkey and its lack of interaction with oral contraceptive steroids. Contraception. 25(3). 307–316. 5 indexed citations
19.
Back, D.J., Mark C. Bates, A. Bowden, et al.. (1980). The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception. 22(5). 495–503. 89 indexed citations
20.
Back, D.J. & Jagmohan Singh. (1976). The biliary excretion of [3H] lysergic acid diethylamide in Wistar and gunn rats. Cellular and Molecular Life Sciences. 32(5). 616–617. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by DJ Back Breakdown of academic impact, for papers by Scott Penzak Breakdown of academic impact, for papers by L.A. Salako Breakdown of academic impact, for papers by Richard C. Brundage Breakdown of academic impact, for papers by Vincent Jullien Breakdown of academic impact, for papers by Juan J.L. Lertora Breakdown of academic impact, for papers by John G. Gambertoglio Breakdown of academic impact, for papers by Indravadan H. Patel Breakdown of academic impact, for papers by James J. Keirns Breakdown of academic impact, for papers by Keith Gallicano
Rankless by CCL
2026